Want to see TSE:AIML full AI Analyst Report?
Top Page
Aiml Resources
(AIML)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.05
▼(-4.00% Downside)
Action:Reiterated
Date:10/03/26
The score is driven primarily by very weak financial performance—shrinking tiny revenue, negative gross profit, large ongoing losses, accelerating cash burn, and negative equity. Technical indicators provide only limited support with mixed momentum signals, and valuation remains unattractive due to losses (negative P/E) and no dividend yield.
Positive Factors
Reported EPS Growth
Reported EPS growth provides one limited sign of improvement in per-share performance despite the company remaining loss-making. If sustained, better EPS progression could eventually support operating recovery, but its durability depends on reversing the broader deterioration in revenue, margins, and cash generation.
Negative Factors
Revenue Contraction
Extremely small and declining revenue indicates weak commercial traction and limited operating scale. A roughly 47% contraction reduces the base available to cover fixed costs, makes profitability harder to reach, and suggests that near-term recovery requires a substantial improvement in demand or monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Reported EPS Growth
Reported EPS growth provides one limited sign of improvement in per-share performance despite the company remaining loss-making. If sustained, better EPS progression could eventually support operating recovery, but its durability depends on reversing the broader deterioration in revenue, margins, and cash generation.
Read all positive factors
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$14.92M
Dividend YieldN/A
Average Volume (3M)246.53K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth-73.93%
EPS Growth23.46%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding298,351,500
10 Day Avg. Volume208,484
30 Day Avg. Volume246,532
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-12.15
Price to Sales (P/S)114.91
P/FCF Ratio-1.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aiml Resources Business Overview & Revenue Model
Company Description
Operating within the digital healthcare sector, AI/ML Innovations Inc. harnesses the power of artificial intelligence (AI) and machine learning (ML). The company's central offering is a patent-pending system for personal health monitoring and mana...
How the Company Makes Money
Reliable, source-verifiable details on Aiml Resources (AIML)'s revenue model, key revenue streams, and material partnerships or drivers of earnings are not available from the context provided. null...
Aiml Resources Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
11
Very Negative
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.06K | 167.31K | 600.14K | 487.50K | 65.41K |
| Gross Profit | -2.75M | 162.81K | 294.86K | 466.01K | 65.41K |
| EBITDA | -6.39M | -4.85M | -1.67M | -1.36M | -3.42M |
| Net Income | -6.36M | -4.59M | -3.29M | -1.42M | -3.17M |
Balance Sheet | |||||
| Total Assets | 2.07M | 3.41M | 329.69K | 1.51M | 2.04M |
| Cash, Cash Equivalents and Short-Term Investments | 257.77K | 2.00M | 216.86K | 14.56K | 525.24K |
| Total Debt | 962.20K | 198.19K | 197.72K | 859.98K | 261.34K |
| Total Liabilities | 2.89M | 855.77K | 1.54M | 1.79M | 1.55M |
| Stockholders Equity | -785.25K | 2.60M | -1.17M | -247.46K | 1.08M |
Cash Flow | |||||
| Free Cash Flow | -5.41M | -3.99M | -1.64M | -634.28K | -3.02M |
| Operating Cash Flow | -5.41M | -3.99M | -1.64M | -634.28K | -3.02M |
| Investing Cash Flow | -4.67K | -1.15K | -325.98K | -210.64K | -1.14M |
| Financing Cash Flow | 3.67M | 5.78M | 2.16M | 374.37K | 1.27M |
Aiml Resources Technical Analysis
Positive
0.05
Price Trends
0.04
Positive
0.05
Positive
0.04
Positive
Market Momentum
<0.01
Negative
59.23
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIML, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.23 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AIML.
Aiml Resources Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$57.80M | -11.62 | 9999.00% | ― | -36.92% | 13.03% | |
45 Neutral | C$10.73M | -1.98 | 64.52% | ― | 7.63% | -106.03% | |
42 Neutral | C$14.92M | -1.92 | 2759.13% | ― | -73.93% | 23.46% | |
42 Neutral | C$6.48M | -1.87 | 6239.15% | ― | 614.03% | 51.97% | |
42 Neutral | C$5.92M | -2.90 | 739.84% | ― | ― | -28.35% | |
41 Neutral | C$4.21M | -1.45 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
TSE:AIML
Aiml Resources
0.05
0.00
0.00%
TSE:ADK
Diagnos
0.48
0.13
37.14%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.37
-0.25
-40.32%
TSE:UDOC
UniDoc Health Corp
0.08
-0.12
-60.53%
TSE:NARA
PanGenomic Health, Inc. Class A
0.30
-1.90
-86.36%
TSE:DMED
DiagnaMed Holdings Corp.
0.05
-0.06
-57.14%
Aiml Resources Corporate Events
Executive/Board ChangesPrivate Placements and Financing
AI/ML Innovations Names New CFO and Issues Shares to Settle Debt
Positive
Oct 2, 2026
AI/ML Innovations Inc., a global technology firm specializing in artificial intelligence and neural-network solutions for digital health, develops platforms that transform biometric data into clinical insights to improve diagnosis, treatment perso...
Business Operations and StrategyProduct-Related Announcements
AIML’s NeuralCloud Strikes VetMed Deal to Validate MaxYield ECG Tech in Preclinical Cardiac Safety
Positive
Oct 1, 2026
AI/ML Innovations’ subsidiary NeuralCloud Solutions has signed a binding commercial term sheet and service level agreement with VetMed Consultants to evaluate the use of its MaxYield ECG signal-processing technology in preclinical cardiac sa...
Business Operations and StrategyProduct-Related Announcements
NeuralCloud and RKS Medical Partner to Pilot Integrated CardioYield Cardiac Monitoring Platform
Positive
Sep 29, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations Inc., has entered a strategic partnership with Toronto-based RKS Medical Technologies to pair NeuralCloud’s CardioYield software with RKS’s myPatch wireless Holter monitoring dev...
Business Operations and StrategyProduct-Related Announcements
AI/ML Innovations Launches Quantum Soma Contactless Quantum Biosensing Initiative
Positive
Sep 21, 2026
AI/ML Innovations has launched Quantum Soma, a new project to develop a contactless quantum biosensing platform that marries Dynex Quantum Technologies’ NV-diamond quantum sensors with AIML’s MaxYield signal-intelligence engine. The in...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
AI/ML’s NeuralCloud Taps Former FDA Lead Reviewer to Head Regulatory Strategy
Positive
Sep 1, 2026
AI/ML Innovations’ subsidiary NeuralCloud has appointed former U.S. FDA lead reviewer and scientist Dr. Mehmet A. Kosoglu as Head of Regulatory, adding more than 15 years of experience in medical devices, SaMD, digital health and FDA policy ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeuralCloud to Pilot AI ECG Platforms with Island Mobile Cardiology Testing
Positive
Aug 18, 2026
NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., has signed a non-binding commercial term sheet with Island Mobile Cardiology Testing to run a pilot of its MaxYield and CardioYield platforms in a mobile Holter monitoring workflo...
Business Operations and StrategyPrivate Placements and Financing
AI/ML Innovations Plans $2 Million Private Placement to Fund Digital Health Expansion
Positive
Aug 14, 2026
AI/ML Innovations Inc., a global AI-driven digital health company, develops proprietary platforms that apply neural networks and deep learning to complex biometric data. Its technology is designed to generate actionable clinical insights that supp...
Business Operations and StrategyRegulatory Filings and Compliance
NeuralCloud Gains ISO 13485 MDSAP Certification for ECG AI Medical Software
Positive
Aug 11, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has obtained ISO 13485:2016 certification under the Medical Device Single Audit Program for its quality management system covering the design, development, production, and distribution of E...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.